Table 1 The main regulatory mechanisms of transcription factor lysine methylation
Mechanism | Substratea | Enzymeb | Tumor type | Transcription activity | References |
|---|---|---|---|---|---|
Protein stability | RORαK38me1 | EZH2 | Breast cancer | Inhibition | |
| Â | RelAK314me1 K315me1 | SET7 | MEFs (mouse cardio myocytes), U2OS(osteosarcoma cell), A549(NSCLC cell) | Inhibition | |
Nuclear localization | P53K372me1 | SET7 | 293F, U2OS(osteosarcoma cell), H1299(NSCLC cell) | Activation | |
|  | ERαK302me1 | SET7 | Breast cancer | Activation | |
DNA-binding affinity | P53K370me1 | SMYD2 | H1299(NSCLC cell), U2OS(osteosarcoma cell), BJ-DNp53(fibroblast cell) | Inhibition | |
|  | HIF1αK32me1 | SET7 | RCC4(renal carcinoma cell) | Inhibition | |
|  | HIF2αK29me1 | SET7 | RCC4(renal carcinoma cell) | Inhibition | |
| Â | P53K382me1 | SET8 | U2OS(osteosarcoma cell), H1299(NSCLC cell) | Inhibition | |
| Â | STAT3 K140me2 | SET7 | DLD1(colon cancer cell) | Inhibition | |
| Â | RelAK37me1 | SET7 | 293T | Activation | |
| Â | RelAK218me1, K221me2 | NSD1 | 293C6, HT29(colon cancer cell) | Activation | |
| Â | ARK632me* | SET7 | Prostate cancer cell | Activation | |
| Â | YY1K173me1, K411me1 | SET7 | HeLa(cervical carcinoma) | Activation | |
| Â | YY2 K247me1 | SET7 | HeLa(cervical carcinoma) | Activation | |
Protein–protein binding | RelAK310me1 | SETD6 | 293T, U2OS(osteosarcoma cell), THP1(mononuclear macrophage) | Inhibition | |
| Â | RBK860me1 | SMYD2 | 293T, U2OS(osteosarcoma cell), NIH3T3(mouse embryonal fibroblast cell) | Activation | |
| Â | RBK873me1 | SET7 | U2OS(osteosarcoma cell), SAOS2(osteosarcoma cell), C2C12(myoblast), CC42 (fibroblast cell) | Activation | |
| Â | P53K382me2 | Unknown | U2OS(osteosarcoma cell) | Activation | |
Crosstalk with other PTMs | GATA4 K299me1 | EZH2 | HL1(mouse cardio myocytes) | Inhibition | |
| Â | RBK810me1 | SET7 | U2OS(Osteosarcoma cell) | Inhibition | |
|  | ERαK266me1 | SMYD2 | Breast cancer | Inhibition | |
| Â | STAT3K180me* | EZH2 | Glioblastoma | Activation |
